Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.

Thaqi A, Scott JL, Gilbert J, Sakoff JA, McCluskey A.

Eur J Med Chem. 2010 May;45(5):1717-23. doi: 10.1016/j.ejmech.2010.01.004. Epub 2010 Jan 14.

PMID:
20153915
2.

Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.

McCluskey A, Bowyer MC, Collins E, Sim ATR, Sakoff JA, Baldwin ML.

Bioorg Med Chem Lett. 2000 Aug 7;10(15):1687-90.

PMID:
10937725
3.

The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?

McCluskey A, Ackland SP, Gardiner E, Walkom CC, Sakoff JA.

Anticancer Drug Des. 2001 Dec;16(6):291-303.

PMID:
12375882
4.

Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines.

McCluskey A, Ackland SP, Bowyer MC, Baldwin ML, Garner J, Walkom CC, Sakoff JA.

Bioorg Chem. 2003 Feb;31(1):68-79.

PMID:
12697169
5.

Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?

McCuskey A, Keane MA, Mudgee LM, Sim AT, Sakoff J, Quinn RJ.

Eur J Med Chem. 2000 Oct;35(10):957-64.

PMID:
11121622
6.

Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.

Hill TA, Stewart SG, Sauer B, Gilbert J, Ackland SP, Sakoff JA, McCluskey A.

Bioorg Med Chem Lett. 2007 Jun 15;17(12):3392-7. Epub 2007 Apr 2.

PMID:
17451951
7.

Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.

Yeh CB, Su CJ, Hwang JM, Chou MC.

Eur J Med Chem. 2010 Sep;45(9):3981-5. doi: 10.1016/j.ejmech.2010.05.053. Epub 2010 Jun 1.

PMID:
20691337
8.

Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition.

Hill TA, Stewart SG, Gordon CP, Ackland SP, Gilbert J, Sauer B, Sakoff JA, McCluskey A.

ChemMedChem. 2008 Dec;3(12):1878-92. doi: 10.1002/cmdc.200800192.

PMID:
19025735
9.

Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A.

Shan HB, Cai YC, Liu Y, Zeng WN, Chen HX, Fan BT, Liu XH, Xu ZL, Wang B, Xian LJ.

Anticancer Drugs. 2006 Sep;17(8):905-11.

PMID:
16940800
10.

Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues.

Sakoff JA, Ackland SP, Baldwin ML, Keane MA, McCluskey A.

Invest New Drugs. 2002 Feb;20(1):1-11.

PMID:
12003183
12.

Mechanistic insight into a novel synthetic cantharidin analogue in a leukaemia model.

Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Wong RS, Cheng GY, Tang WK, Cheng CH, Tang JC, Chan AS.

Int J Mol Med. 2006 Aug;18(2):375-9.

PMID:
16820948
13.

Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin).

Baba Y, Hirukawa N, Tanohira N, Sodeoka M.

J Am Chem Soc. 2003 Aug 13;125(32):9740-9.

PMID:
12904040
14.

Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines.

Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Cheng GY, Wong RS, Lai PP, Leung TW, Tang JC, Chan AS.

Int J Mol Med. 2006 May;17(5):945-9.

PMID:
16596285
15.

Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.

Vicker N, Burgess L, Chuckowree IS, Dodd R, Folkes AJ, Hardick DJ, Hancox TC, Miller W, Milton J, Sohal S, Wang S, Wren SP, Charlton PA, Dangerfield W, Liddle C, Mistry P, Stewart AJ, Denny WA.

J Med Chem. 2002 Jan 31;45(3):721-39.

PMID:
11806724
16.

Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.

McCluskey A, Walkom C, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA.

Bioorg Med Chem Lett. 2001 Nov 19;11(22):2941-6.

PMID:
11677131
17.

The effects of cantharidin and cantharidin derivates on tumour cells.

Liu D, Chen Z.

Anticancer Agents Med Chem. 2009 May;9(4):392-6. Review.

PMID:
19442040
18.

The first two cantharidin analogues displaying PP1 selectivity.

McCluskey A, Keane MA, Walkom CC, Bowyer MC, Sim AT, Young DJ, Sakoff JA.

Bioorg Med Chem Lett. 2002 Feb 11;12(3):391-3.

PMID:
11814804
19.

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM.

J Med Chem. 1998 Aug 13;41(17):3276-92.

PMID:
9703473
20.

Induction of apoptosis on carcinoma cells by two synthetic cantharidin analogues.

Kok SH, Chui CH, Lam WS, Chen J, Tang JC, Lau FY, Cheng GY, Wong RS, Chan AS.

Int J Mol Med. 2006 Jan;17(1):151-7.

PMID:
16328024

Supplemental Content

Support Center